THRIVE
Research type
Research Study
Full title
TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS
IRAS ID
344990
Contact name
Helen Reeves
Contact email
Sponsor organisation
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe) and it the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is a difficult to cure cancer (curation rate ~30%) with poor outcomes (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of biomarkers that help us choose the best therapy for individual patients - called 'precision medicine'.
THRIVE aims to improve the outcome of liver cancer patients by understanding at-risk populations and key interactions between the tumour and the affected person, or 'host'. We aim to identify biomarkers, ideally in blood or biopsy tissues, that help to choose the best treatment. With improved knowledge, we aim to develop novel, affordable treatments, that will be well-tolerated and overcome resistance.
THRIVE brings together 13 partners from 8 countries and expects to;
1. Define molecular features of liver cancer predisposition in those at risk.
2. Develop a human liver cancer blueprint of tumour, non-tumour and immune cells.
3. Identify AI-based molecular markers of liver cancer development and response to treatments.
4. Implement a pre-clinical drug testing platform for discovery of affordable therapies with high social impact.
5. Improve outcomes for patients at risk of and with liver cancer.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
24/NW/0366
Date of REC Opinion
10 Jan 2025
REC opinion
Further Information Favourable Opinion